New discovery to aid in diagnosis and treatment of kidney disease

July 1, 2009

Researchers from Boston University School of Medicine (BUSM) in collaboration with scientists at the University of Louisville and the University of Nice Sophia Antipolis in France, have identified the target antigen PLA2R in patients with idiopathic membranous nephropathy (kidney disease), which has implications for the diagnosis and treatment of this disease. These findings appear in the July 2 issue of the New England Journal of Medicine.

Idiopathic membranous nephropathy involves the thickening and dysfunction of the filtering parts of the kidneys called glomeruli. It is caused when antibodies attack the glomeruli causing large amounts of protein to leak into the urine. It is a relatively common cause of adult-onset kidney disease that can progress over time to cause . Until now, the diagnosis of membranous nephropathy required a kidney biopsy as there are no blood or urine tests to specifically distinguish membranous nephropathy from other causes of . This is because up until now the protein that is the target of the circulating auto-antibodies has never been identified.

To identify the target antigen in patients with this condition, the researchers used circulating antibodies from adults with this disease to detect normal glomerular proteins. Subsequent analysis with the use of mass spectrometry and confirmation with the use of protein-specific reagents allowed for identification and characterization of the predominant protein detected by these circulating antibodies.

According to the researchers this discovery has important implications for both the diagnosis and treatment of membranous nephropathy. "Identifying the antigen will enable development of a simple blood test that could replace the need for a kidney biopsy and establish which patients are most likely to benefit from immunosuppressive treatment," said senior author David Salant, MD, a professor of medicine at BUSM and chief of the renal section at Boston Medical Center.

"Our findings show that PLA2R is a major target antigen in idiopathic membranous nephropathy. Seventy percent of our patients with biopsy-proven idiopathic membranous nephropathy had IgG antibodies that reacted with PLA2R, a constituent of normal human glomeruli," he added.

Source: Boston University Medical Center


Rank not rated yet
Relevant PhysicsForums posts

More news stories

Team isolates nerve cells involved in storing long term memory and gene proteins associated with them

(Medical Xpress) -- A research team in Taiwan has succeeded in isolating two nerve cells in fruit fly brains that are believed to be the major players in allowing for the formation of long term memories. Furthermore, ...

Medicine & Health / Neuroscience

created 55 minutes ago | popularity 5 / 5 (3) | comments 0 | with audio podcast report

News of plaque-clearing drug tops week of major advances against Alzheimer's disease

In the last eight days, scientists have delivered a powerful one-two punch in the fight to defeat Alzheimer's disease. At the same time, the White House and members of Congress are proposing increases in Alzheimer's research ...

Medicine & Health / Diseases

created 51 minutes ago | popularity not rated yet | comments 1

To avoid early labor and delivery, weight and diet changes not the answer

One of the strongest known risk factors for spontaneous or unexpected preterm birth – any birth that occurs before the 37th week of pregnancy, most often without a known cause – is already having had one. For women ...

Medicine & Health / Health

created 4 minutes ago | popularity not rated yet | comments 0 | with audio podcast

Joint patent for using the BRCA1 gene as a therapy for cardiovascular disease

St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.

Medicine & Health / Genetics

created 20 minutes ago | popularity not rated yet | comments 0

S.Africa in $208 mln AIDS drug venture with Swiss Lonza

South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.

Medicine & Health / HIV & AIDS

created 1 hour ago | popularity not rated yet | comments 0


The power of estrogen -- male snakes attract other males

A new study has shown that boosting the estrogen levels of male garter snakes causes them to secrete the same pheromones that females use to attract suitors, and turned the males into just about the sexiest ...

Could Venus be shifting gear?

(PhysOrg.com) -- ESA’s Venus Express spacecraft has discovered that our cloud-covered neighbour spins a little slower than previously measured. Peering through the dense atmosphere in the infrared, the ...

Experts reveal how plants don't get sunburn

(PhysOrg.com) -- Experts at the University of Glasgow have discovered how plants survive the harmful rays of the sun.

Fool's gold may prove an unlikely alternative to overexploited catalytic materials

Catalytic materials, which lower the energy barriers for chemical reactions, are used in everything from the commercial production of chemicals to catalytic converters in car engines. However, with current catalytic materials ...

SLAC, Stanford team focuses on high-energy electrons to treat cancer

Accelerator physicists at SLAC and cancer specialists from Stanford are working on a new technology that could dramatically reduce the time needed for cancer radiation treatments. The team ran an initial experiment ...

Unpicking HIV’s invisibility cloak

Drug researchers hunting for alternative ways to treat human immunodeficiency virus (HIV) infections may soon have a novel target—its camouflage coat. HIV hides inside a cloak unusually rich in a sugar ...